Benzinga | Nov 9, 2020 07:39AM EST

Intra-Cellular Therapies Q3 EPS $(0.79) Beats $(1.00) Estimate, Sales $7.37M Beat $5.86M Estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.00) by 21 percent. This is a 25.4 percent decrease over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $7.37 million which beat the analyst consensus estimate of $5.86 million by 25.75 percent.